For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Ginkgo Bioworks Holdings Inc’s stock clocked out at $12.38, down -8.43% from its previous closing price of $13.52. In other words, the price has decreased by -$8.43 from its previous closing price. On the day, 1.47 million shares were traded. DNA stock price reached its highest trading level at $14.04 during the session, while it also had its lowest trading level at $12.1801.
Ratios:
To gain a deeper understanding of DNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.79 and its Current Ratio is at 5.79. In the meantime, Its Debt-to-Equity ratio is 0.56 whereas as Long-Term Debt/Eq ratio is at 0.56.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 11 ’25 when Che Austin bought 99 shares for $13.24 per share.
Che Austin bought 99 shares of DNA for $1,445 on Feb 10 ’25. On Feb 07 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $13.91 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 711588800 and an Enterprise Value of 503826848. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.26 while its Price-to-Book (P/B) ratio in mrq is 0.78. Its current Enterprise Value per Revenue stands at 2.312 whereas that against EBITDA is -0.958.
Stock Price History:
The Beta on a monthly basis for DNA is 1.16, which has changed by -0.7731544 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $64.40, while it has fallen to a 52-week low of $5.26. The 50-Day Moving Average of the stock is 12.64%, while the 200-Day Moving Average is calculated to be -7.49%.
Shares Statistics:
It appears that DNA traded 1.53M shares on average per day over the past three months and 1827810 shares per day over the past ten days. A total of 41.37M shares are outstanding, with a floating share count of 36.49M. Insiders hold about 33.02% of the company’s shares, while institutions hold 48.06% stake in the company. Shares short for DNA as of 1738281600 were 8253002 with a Short Ratio of 5.10, compared to 1735603200 on 7374291. Therefore, it implies a Short% of Shares Outstanding of 8253002 and a Short% of Float of 24.790001.
Earnings Estimates
The current assessment of Ginkgo Bioworks Holdings Inc (DNA) involves the perspectives of 1.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$9.92 and -$9.92 for the fiscal current year, implying an average EPS of -$9.92.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $44.43M. It ranges from a high estimate of $46.8M to a low estimate of $43.1M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $34.76MFor the next quarter, 5 analysts are estimating revenue of $44.24M. There is a high estimate of $47M for the next quarter, whereas the lowest estimate is $40M.
A total of 6 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $230M, while the lowest revenue estimate was $226.3M, resulting in an average revenue estimate of $227.68M. In the same quarter a year ago, actual revenue was $251.46MBased on 6 analysts’ estimates, the company’s revenue will be $203.81M in the next fiscal year. The high estimate is $220.03M and the low estimate is $190M.
